Anti-CGRP Therapy Re-Imagined
The world's 1st prospective treatment outcome predictor for anti-CGRP therapy
CGRP Diagnostics: Transforming migraine management
The Problem
Anti-CGRP therapy is the biggest advance in migraine treatment in 30 years – but it only works for about 50% of patients, and is often reserved until after multiple treatment failures. To date, it has been impossible to identify which patients, pre-treatment, are likely to respond to anti-CGRP drugs of any kind. All that has now changed…
The CGRP Diagnostics Solution
A discovery identified non-ictal allodynia as the key to accurately predicting pre-treatment anti-CGRP therapy response. Together with CGRP Diagnostics, they developed the world’s first neurology “theranostic” – a proprietary Treatment Outcome Predictor test, clinically validated to prospectively identify which patients will, or won’t, respond to anti-CGRP therapy – transforming migraine management for patients, clinicians and payors.-
CGRPDx: The Right Direction for Better Outcomes
Earlier Treatment: Accurate pre-treatment prediction of likely therapeutic success enables earlier patient access to anti-CGRP therapy
Precision Approach: Preferred by patients and clinicians, providing confidence to prescribe, requiring fewer Gx failures for responders, and allowing non-responders to be quickly triaged to alternative solutions (reducing cost and frustration)
Differentiated and Effective: First-line therapy positioning, moving anti-CGRP therapy to earlier in treatment protocols, patients remain on effective therapy longer
World-Leading Science
CGRP Diagnostics is proud to have a team of world-leading scientists at its core:
Prof. Messoud Ashina, DMSc, PhD
Professor of Neurology, University of Copenhagen, Past-President of IHS
Prof. Richard B. Lipton, M.D
Professor of Neurology, Einstein College of Medicine, AHS Past-President
Iris Grossman, PhD
Scientific Founding Advisor & leading precision medicine expert
Mark Hasleton, PhD
CEO of CGRP Diagnostics
Proven Accuracy
The data behind first ever predictive test for anti-CGRP treatment success have been accepted for publication in Cephalalgia, showing that non-ictal cephalic allodynia is an accurate marker for prediction of anti-CGRP response. A link to the published manuscript will be posted here when available.
Broad IP Protection
CGRP Diagnostics' IP relates to all available anti-CGRP therapies and methods of testing for allodynia, covering rights on the use of the test with any anti-CGRP drug, valid through at least 2042.